{
  "id": 18797888,
  "title": "Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials",
  "url": "https://urgent.news/2026/11/07/forget-lilly-and-novo-pfizer-is-planning-a-wave-of-phase-3-obesity-18797888",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-07T21:35:00.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/forget-lilly-and-novo-pfizer-planning-wave-phase-3-obesity-trials"
  },
  "original_language": "en",
  "account": null,
  "summary": "Key PointsEli Lilly is the leader in the GLP-1 weight-loss space, with Novo Nordisk working hard to regain lost market share.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials",
        "url": "https://urgent.news/2026/11/07/forget-lilly-and-novo-pfizer-is-planning-a-wave-of-phase-3-obesity",
        "published": "2026-11-07T21:15:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}